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Risks of Initiating Therapy With
Sotalol for Treatment of
Atrial Fibrillation*
FRANK I. MARCUS, MD, FACC
Tucson, Arizona
In this issue of the Journal, Chung et al. (1) reviewed compli-
cations of sotalol for treatment of atrial arrhythmias in a
retrospective analysis of 120 patients in whom sotalol was
initiated in the hospital. Because 97.5% of the patients were
treated for atrial fibrillation or flutter the study was essentially
an evaluation of treatment of this particular arrhythmia. Of
these 120 patients, 25 (21%) had 35 complications, including 7
(6%) who developed ventricular arrhythmias, 2 of whom had
torsade de pointes. The patient cohort was unique when
compared with that of other reported trials of sotalol for
treatment of atrial fibrillation. For example, 24% of patients
had permanent pacemakers before the onset of antiarrhythmic
therapy. It is therefore not surprising that absence of the
pacemaker was the only significant predictor of arrhythmia
complications because bradycardia was the most frequent
arrhythmia reported. In addition, 12 patients (10%) had a
history of sustained ventricular tachycardia or ventricular
fibrillation before the start of sotalol therapy. It is well known
that patients with sustained ventricular arrhythmias have a
higher incidence of proarrhythmia with sotalol. Therefore, it is
not unexpected that seven of the patients (6%) developed new
onset or increased ventricular arrhythmias. The percentage of
arrhythmia complications was enhanced by the inclusion of
bradycardia at a rate of ,40 beats/min, even during sleep, as
“significant arrhythmias.” Of the two patients reported as
having torsade de pointes, one had a potassium level of 3.4
mmol/liter from diuretic therapy. Hypokalemia, even in the
low “normal range” of 3.5 to 3.9 mmol/liter, is a known risk
factor for torsade de pointes. The other patient had an
implantable cardioverter-defibrillator and developed polymor-
phic ventricular tachycardia. It may be difficult to differentiate
torsade de pointes from polymorphic ventricular tachycardia
unless the classic pattern of the short–long sequence is present,
as well as a markedly prolonged QT. It should be mentioned
that 24 of the patients had no underlying heart disease. Of
these 24, 2 developed bradycardia, and 1 had increased ven-
tricular ectopic beats that led to discontinuation of sotalol. I
would entirely agree with the authors that many, if not the
majority, of patients analyzed in this series should have sotalol
initiated under telemetric surveillance in the hospital.
Before one accepts the general recommendation of Chung
et al. that sotalol treatment for atrial fibrillation should be
started in the hospital, the experience of other investigators
should be reviewed. Although most of the studies were trials
comparing sotalol with other antiarrhythmic drugs, such as
propafenone and quinidine, this editorial comment focuses on
considerations of safety during the initiation of treatment with
sotalol for atrial fibrillation (Table 1).
In the accumulated experience of 384 patients treated with
sotalol for persistent or paroxysmal atrial fibrillation only 1 had
torsade de pointes during the first few days of treatment, and
this patient had a serum potassium level of 3.7 mmol/liter
(2–9). Bradycardia was frequent but not life threatening and
was often asymptomatic. A few patients required a permanent
pacemaker to allow continuation of treatment with sotalol. The
bradycardia usually resolved by decreasing the dose or stop-
ping the drug. It should be emphasized that the patients
reported in these series had a wide variety of conditions. Most
had coronary ischemic heart disease or hypertension, but there
were patients with valvular disease. A minority of patients who
had no evidence of cardiac disease were also included.
If outpatient treatment with sotalol for treatment of atrial
fibrillation is contemplated, the incidence of torsade de
pointes, the major life-threatening cardiovascular complica-
tion, must be nil. How can this frightening proarrhythmic
complication be avoided? There are now a number of risk
factors for torsade de pointes from sotalol that have been
identified. Of these, one that has been repeatedly implicated is
a serum potassium level ,4.0 mmol/liter at baseline (10). To
avoid hypokalemia, patients receiving sotalol for treatment of
atrial fibrillation should not be taking concomitant diuretic
therapy. If they are, it should be demonstrated over weeks or
months they have stable levels of potassium .4.0 mmol/liter,
and serum potassium levels should be checked frequently after
treatment with sotalol. Other factors predisposing to torsade
de pointes in patients receiving sotalol in decreasing order of
importance are female gender, sustained ventricular arrhyth-
mia, history of congestive heart failure and sotalol dose
.320 mg daily (11,12). Patients who developed torsade de
pointes had longer baseline and maximal corrected QT (QTc)
intervals, as well as greater changes in the mean value of these
intervals on the electrocardiogram (ECG). Juul-Mo¨ller et al.
(3) found that lower maintenance doses of sotalol appear to be
as effective as higher doses in maintaining normal sinus
rhythm. Therefore, dose as a risk factor can be eliminated by
restricting the dose to 80 mg twice a day, with an upper limit of
320 mg/day in patients with recurrences. Because sotalol is
excreted entirely by renal mechanisms, and because creatinine
clearance is often decreased by 50% in patients .65 years old,
the dose of sotalol may need to be lower in the elderly (13).
Therefore, in elderly patients it is advisable to start with a dose
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of 40 mg twice a day for 1 day and observe whether an
excessive prolongation of the QT interval or significant brady-
cardia occurs before proceeding to higher doses.
Most of the early experience with risk factors for torsade de
pointes came from experience with quinidine (14). With that
drug, torsade de pointes was most commonly observed after
cardioversion to normal sinus rhythm with a slow ventricular
response. Thus, it may be safer to convert atrial fibrillation to
sinus rhythm electrically and reassess suitability for treatment
with sotalol 2 h after resumption of sinus rhythm, as was done
by Juul-Mo¨ller et al. (3), rather than start sotalol before
electrical cardioversion. This strategy provides an opportunity
to more accurately measure the QT interval and look for sinus
bradycardia. The success rate of reversion to sinus rhythm with
direct current cardioversion has been reported to be 86% in
patients with chronic atrial fibrillation not treated with antiar-
rhythmic drugs (15). Information (prior to drug administra-
tion) that can be obtained from the surface ECG that could
predict an increased likelihood of QTc interval prolongation
(.500 ms) includes a marked increase in the QT interval after
a pause, postextrasystolic T wave abnormality and failure of
the QT interval to appropriately shorten during autonomic
stimulation maneuvers, such as the Valsalva maneuver, or
during exercise (16). Identification of patients receiving anti-
Table 1. Adverse Effects During Initiation of Sotalol for Atrial Fibrillation
Study (ref no.)
Year
Published
No.
of
Pts Type of A Fib
Dose
(mg bid)
Adverse Effect
CommentBradycardia
Torsade
de Pointes Other
Antman et al.
(2)
1990 48 PAF and CAF 80–160 10% 0 $ 1 antiarrhythmic drugs failed,
including propafenone before entry;
exclusion included LVEF , 20%
Juul-Mo¨ller et al.
(3)
1990 97 CAF 80 — 1* 4%† Sotalol started 2 h after DC
cardioversion; exclusions included
sick sinus syndrome, serum
potassium , 3.7 mmol/liter,
QTc . 450 ms or HR , 50 beats/
min after cardioversion
Crijns et al.
(4)
1991 39 CAF 269 6 49
(total
daily
dose)
7.6% 0 In 1 pt the drug facilitated
AV node reentrant
tachycardia and CHF
Hohnloser et al.
(5)
1995 25 CAF 80 on day 1;
160 on
days 2–7
— 0 Not stated for period of
drug initiation
Exclusions included NYHA class IV
CHF; serum potassium , 4.0 mmol/
liter; serum creatinine . 1.8 mmol/
liter
Singh et al.
(6)
1991 24 CAF 40–160 8%‡ 0
Reimold et al.
(7)
1993 50 PAF and CAF 80–160 8%§ 0 1§ $ 1 antiarrhythmic drug failed before
entry; exclusion included LVEF
, 30%
Lee et al.
(8)
1997 38 PAF 80 5% 0 Severe dyspnea in 2 pts Sotalol started out of hospital; exclusion
included NYHA class IV CHF; sick
sinus syndrome; sinus bradycardia
, 60 beats/min, SBP , 90 mm Hg;
“clinically significant” electrolyte
abnormalities
Wanless et al.
(9)
1997 81 SVT, including
63 with
PAF or
paroxysmal
A flutter
80 or
160 mg
0 6 pts\ Sotalol started outside the hospital;
exclusions included HR
, 50 beats/min, sick sinus syndrome,
QTc . 0.45 s, electrolyte imbalance
*The one patient who developed torsade de points had a serum potassium level of 3.7 mmol/liter; in addition the QT interval prolonged to 0.67 s, and she developed
bradycardia of 47 beats/min, which occurred on day 2 of treatment with sotalol (80 mg twice daily). †Adverse effects within 1 week of therapy; no further details given.
‡Paroxysmal atrial fibrillation (PAF) and chronic atrial fibrillation (CAF). §Not stated if this occurred during initiation of sotalol or during follow-up. \Not stated when
they occurred; no ventricular proarrhythmia or congestive heart failure; “typical beta-blocking side effects, including bradycardia, dyspnea and fatigue.” A Fib 5 atrial
fibrillation; A flutter 5 atrial flutter; AV 5 atrioventricular; bid 5 twice daily; CHF 5 congestive heart failure; DC 5 direct current; HR 5 heart rate; LVEF 5 left
ventricular ejection fraction; NYHA 5 New York Heart Association; Pts 5 patients; QTc 5 corrected QT interval; ref 5 reference; SBP 5 systolic blood pressure.
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
QTc 5 corrected QT interval
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arrhythmic drug therapy at risk for torsade de pointes is aided
not only by measurement of the QT interval but also by
observing the appearance of prominent U waves, which can be
equal to or greater in amplitude than the T wave (17,18), or
abnormal QTU prolongation and distortion after pauses
(19,20). A paradoxic increase in the QTc interval was observed
during exercise in 11 patients taking class 1A antiarrhythmic
drugs who developed polymorphic ventricular tachycardia
compared with patients taking these drugs who did not develop
this arrhythmia (21). Technology has now been developed to
measure the QT interval from a 24-h Holter recording. This
technology could permit outpatient assessment of the QT
interval during treatment with low dose sotalol (22,23). It has
been reported (24) that excessive prolongation of the QTc
interval during treatment with sotalol may be predictive of a
predisposition to torsade de pointes.
There is limited experience with initiating antiarrhythmic
drug therapy for treatment of atrial fibrillation on an outpa-
tient basis. Prystowsky (25) reviewed the published reports on
complications associated with starting antiarrhythmic drug
therapy for atrial fibrillation using a variety of antiarrhythmic
drugs. He concluded that patients without structural heart
disease, sinus node dysfunction or atrioventricular conduction
abnormalities who have a normal baseline QT interval do not
need to be admitted to the hospital for initiation of drug
therapy. However, patients with heart disease should be ob-
served in the hospital when quinidine, disopyramide, procain-
amide, amiodarone or sotalol are prescribed. The recently
published American Heart Association Guidelines (26) for
management of patients with atrial fibrillation states that
proarrhythmia is relatively rare in patients without heart
disease and that initiation of antiarrhythmic treatment is
reasonable in this select patient population. This document
also states that patients with ventricular hypertrophy may be at
increased risk for developing torsade de pointes, although this
statement was not based on clinical data.
Maisel et al. (27) performed a retrospective chart review of
597 drug trials for treatment of atrial fibrillation. Antiarrhyth-
mic drugs included procainamide, quinidine, disopyramide,
propafenone and sotalol. Structural heart disease was present
in 90% of patients. Of the 72 patients treated with sotalol, the
usual dose was 80 mg twice a day. Eight of these patients had
bradyarrhythmias. It is not stated whether these required
immediate therapy other than decreasing the dose or stopping
the drug. Two patients treated with sotalol had nonsustained
ventricular tachycardia. One patient had QT interval prolon-
gation. Recently a trial of outpatient initiation of antiarrhyth-
mic drug therapy for patients with atrial fibrillation was
reported (28). There were 113 patients who were in sinus
rhythm after having undergone cardioversion or had reverted
spontaneously. Patients with ventricular arrhythmias, the long
QT syndrome or an implanted pacemaker were excluded.
Transtelephonic monitoring of ECGs was performed daily.
Patients were followed up for 10 days. Sotalol was used in 12
patients. Of these 12 patients, 1 developed QT prolongation
.0.50 ms, leading to discontinuation of the drug, and 1
developed symptomatic bradycardia with subsequent perma-
nent pacemaker implantation. Torsade de pointes was not
observed. All these adverse effects with sotalol occurred be-
yond the usual 72 h period for inpatient antiarrhythmic drug
monitoring. Chung et al. (1) concluded that outpatient initia-
tion of antiarrhythmic drug therapy using transtelephonic
monitoring after cardioversion of atrial fibrillation or flutter is
safe.
By selecting patients who have a low risk for torsade de
pointes, utilizing low doses and by careful outpatient ECG
monitoring, there is evidence that sotalol can be initiated safely
on an outpatient basis for the treatment of atrial fibrillation or
flutter. It would seem that the risk of torsade de pointes or
severe bradycardia may be minimized if the drug is started
after cardioversion. It is likely that this strategy can be applied
safely to patients with underlying heart disease, such as those
with a history of hypertension, coronary ischemic heart disease
or valvular heart disease.
To hospitalize or not to hospitalize for initiating treatment
with sotalol—that is the question. Whether ’tis safer to do so or
risk the unlikely event of torsade de pointes and bring on the
wrath of the malpractice lawyers is yet unknown. This is the
question that must be answered by prospective clinical trials.
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